Lexeo Therapeutics, Inc. Common Stock (LXEO) - Total Assets
Based on the latest financial reports, Lexeo Therapeutics, Inc. Common Stock (LXEO) holds total assets worth $143.84 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lexeo Therapeutics, Inc. Common Stock book value and equity for net asset value and shareholders' equity analysis.
Lexeo Therapeutics, Inc. Common Stock - Total Assets Trend (2020–2024)
This chart illustrates how Lexeo Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Lexeo Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Lexeo Therapeutics, Inc. Common Stock's total assets of $143.84 Million consist of 85.8% current assets and 14.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Lexeo Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LXEO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lexeo Therapeutics, Inc. Common Stock's current assets represent 85.8% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, down from 99.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lexeo Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Lexeo Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Lexeo Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.40 | 5.95 | 5.58 |
| Quick Ratio | 7.40 | 5.95 | 5.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $110.52 Million | $132.64 Million | $65.70 Million |
Lexeo Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Lexeo Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.81 |
| Latest Market Cap to Assets Ratio | 2.87 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | $146.94 Million |
| Market Capitalization | $421.14 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lexeo Therapeutics, Inc. Common Stock's assets at a significant premium (2.87x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Lexeo Therapeutics, Inc. Common Stock's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Lexeo Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total assets of Lexeo Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $146.94 Million | +5.10% |
| 2023-12-31 | $139.81 Million | +44.02% |
| 2022-12-31 | $97.08 Million | -29.07% |
| 2021-12-31 | $136.86 Million | +365.36% |
| 2020-12-31 | $29.41 Million | -- |
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a… Read more